Laura Viviani1, Michael J Harrison2, Anna Zolin1, Charles S Haworth2, R Andres Floto3. 1. Dipartimento di Scienze cliniche e di comunità, University of Milan, Italy. 2. Cambridge Centre for Lung Infection, Papworth Hospital, Cambridge, UK. 3. Cambridge Centre for Lung Infection, Papworth Hospital, Cambridge, UK; Cambridge Institute for Medical Research, University of Cambridge, UK. Electronic address: arf27@cam.ac.uk.
Abstract
BACKGROUND: Infection by nontuberculous mycobacteria (NTM) in patients with cystic fibrosis (CF) is often associated with significant morbidity. Limited, conflicting results are published regarding risk factors for pulmonary NTM disease. We analysed factors potentially associated with NTM in a large population of European patients with CF. METHODS: We investigated associations between presence of NTM and various factors for patients registered in the European Cystic Fibrosis Society Patient Registry. RESULTS: 374 (2.75%) of 13,593 patients studied had at least one positive NTM culture within the study year. Age- and FEV1-adjusted odds of NTM infection was more than 2.5 times higher (95%CI: 1.79; 3.60) in patients infected by Stenotrophomonas maltophilia than in patients not infected (p<0.0001), 2.36 times higher (95%CI: 1.80;3.08) in patients with ABPA than without (p<0.0001), 1.79 times higher (95%CI: 1.34; 2.38) in patients who use bronchodilators than in patients who don't (p<0.0001), 1.49 times higher (95%CI: 1.18; 1.89) in patients who use inhaled antibiotics than in patients who don't (p=0.001), and 1.30 times higher (95%CI: 1.02; 1.66) in patients who use rhDNase than in patients who don't (p=0.032). CONCLUSIONS: NTM-positive cultures in individuals with CF are associated with distinct clinical variables. Improved data collection identifying risk factors for NTM infection will allow more focused screening strategies, and influence therapeutic choices and infection control measures in high-risk patients.
BACKGROUND:Infection by nontuberculous mycobacteria (NTM) in patients with cystic fibrosis (CF) is often associated with significant morbidity. Limited, conflicting results are published regarding risk factors for pulmonary NTM disease. We analysed factors potentially associated with NTM in a large population of European patients with CF. METHODS: We investigated associations between presence of NTM and various factors for patients registered in the European Cystic Fibrosis SocietyPatient Registry. RESULTS: 374 (2.75%) of 13,593 patients studied had at least one positive NTM culture within the study year. Age- and FEV1-adjusted odds of NTM infection was more than 2.5 times higher (95%CI: 1.79; 3.60) in patients infected by Stenotrophomonas maltophilia than in patients not infected (p<0.0001), 2.36 times higher (95%CI: 1.80;3.08) in patients with ABPA than without (p<0.0001), 1.79 times higher (95%CI: 1.34; 2.38) in patients who use bronchodilators than in patients who don't (p<0.0001), 1.49 times higher (95%CI: 1.18; 1.89) in patients who use inhaled antibiotics than in patients who don't (p=0.001), and 1.30 times higher (95%CI: 1.02; 1.66) in patients who use rhDNase than in patients who don't (p=0.032). CONCLUSIONS: NTM-positive cultures in individuals with CF are associated with distinct clinical variables. Improved data collection identifying risk factors for NTM infection will allow more focused screening strategies, and influence therapeutic choices and infection control measures in high-risk patients.
Authors: Franziska S Birmes; Ruth Säring; Miriam C Hauke; Niklas H Ritzmann; Steffen L Drees; Jens Daniel; Janina Treffon; Eva Liebau; Barbara C Kahl; Susanne Fetzner Journal: Infect Immun Date: 2019-09-19 Impact factor: 3.441
Authors: William J Richter; Yuqing Sun; Kevin J Psoter; Matthew N Santos; Jan A Nguyen; Aniket Sidhaye; Noah Lechtzin; Mark T Jennings; Keira A Cohen Journal: Ann Am Thorac Soc Date: 2021-05
Authors: Luis Máiz; Rosa Nieto; Rafael Cantón; Elia Gómez G de la Pedrosa; Miguel Ángel Martinez-García Journal: Int J Mol Sci Date: 2018-01-04 Impact factor: 5.923
Authors: Aaron I Gardner; Elliot McClenaghan; Gemma Saint; Paul S McNamara; Malcolm Brodlie; Matthew F Thomas Journal: Clin Infect Dis Date: 2019-02-15 Impact factor: 9.079
Authors: Jerry A Nick; D Rebecca Prevots; Ettie M Lipner; James L Crooks; Joshua French; Michael Strong Journal: J Expo Sci Environ Epidemiol Date: 2021-07-03 Impact factor: 5.563